Ongoing clinical studies

Carag is currently conducting multiple clinical investigations and a post-market registry.

CBMS probe CBMS probe


"Evaluation of the safety and efficacy of the Carag Bioresorbable Septal Occluder (CBSO) to treat patients with clinically significant secundum atrial septal defect"

  • Recently approved by U.S. FDA
  • Stay tuned for additional information

CBSO registry

"Multi centre, international, post market registry to monitor the clinical performance and safety of an atrial septal closure device with bioresorbable framework in patients with clinically significant atrial septum defect (ASD) or patent foramen ovale (PFO) in routine clinical use"

  • Post-market registry with CE marked device
  • Carag is currently recruiting centers in Germany and Switzerland (adult and pediatric)
  • Contact us for further details

CTOM study

"NIRS to monitor abdominal tissue oxygen saturation in preterm infants in an open mono-centric study"

  • A clinical investigation to assess feasibility and safety of a new NIRS device measuring the abdominal tissue oxygen saturation
  • Preterm infants with gestation age less then 35 weeks 
  • Now recruiting at UniversityHospital Zurich Department of Neonatology

CBMS study

"Clinical pilot study to evaluate a new multi-parameter neuromonitoring device that allows the measurement of regional cerebral blood flow (rCBF), intracranial pressure (ICP), brain temperature monitoring and ventricular cerebrospinal fluid (CSF) drainage in brain-injured patients."

  • Now recruiting at Lausanne University Hospital Departement of Intensive Care Medicine

We were very pleased to welcome Jérôme Bernhard as a speaker for an academic symposium on "Clinical Studies with Medical Devices". He shared his broad expertise on medical device development and gave an excellent overview going through the different steps from the idea to the product – showing the way through the multitude of standards and regulations to market approval and beyond.

Dr. Fabian Tay, Specialist in Pharmaceutical Medicine, Zurich

Bioresorbable devices are the definite future of treating congenital and structural heart disease. With the Carag Bioresorbable Septal Occluder (CBSO) we are opening this new clinical chapter and might treat atrial septal defects in patients of all ages with a new device, that is soft, thin and has no metal structure (e.g. nitinol wires). This might influence and improve long term performance of implants, especially in children.

Prof. Dr. Stephan Schubert, Pediatric Cardiologist and Interventionalist, Berlin

    Discover the products